Ensysce Biosciences, Inc. Quarterly Operating Income (Loss) in USD from Q3 2017 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ensysce Biosciences, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2017 to Q4 2024.
  • Ensysce Biosciences, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$3.58M, a 13.3% decline year-over-year.
  • Ensysce Biosciences, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$6.73M, a 37.2% increase year-over-year.
  • Ensysce Biosciences, Inc. annual Operating Income (Loss) for 2024 was -$6.73M, a 37.2% increase from 2023.
  • Ensysce Biosciences, Inc. annual Operating Income (Loss) for 2023 was -$10.7M, a 55.8% increase from 2022.
  • Ensysce Biosciences, Inc. annual Operating Income (Loss) for 2022 was -$24.2M, a 21.9% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 -$3.58M -$421K -13.3% Dec 31, 2024 10-K 2025-03-10
Q3 2024 $645K +$3.35M Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$1.96M +$339K +14.8% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$1.84M +$718K +28% Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$3.16M +$3.05M +49.1% Dec 31, 2023 10-K 2025-03-10
Q3 2023 -$2.71M +$3.46M +56.1% Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$2.29M +$4.76M +67.5% Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$2.56M +$2.24M +46.7% Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$6.2M -$4.15M -203% Dec 31, 2022 10-K 2024-03-15
Q3 2022 -$6.16M +$10.7M +63.5% Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$7.06M -$6.64M -1610% Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$4.8M -$4.28M -816% Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$2.05M -$1.61M -373% Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$16.9M -$16.5M -4072% Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$413K -$552K -397% Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$524K +$391K +42.7% Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$432K +$1.5M +77.6% Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$405K +$180K +30.7% Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $139K +$765K Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$915K -$726K -384% Mar 31, 2020 10-Q 2021-06-08
Q4 2019 -$1.93M -$1.7M -741% Dec 31, 2019 10-K/A 2021-06-08
Q3 2019 -$584K -$336K -135% Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$626K -$314K -101% Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$189K -$19K -11.2% Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$229K -$82.7K -56.4% Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$248K -$243K -4864% Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$312K Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$170K Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$147K Dec 31, 2017 10-K/A 2019-03-12
Q3 2017 -$5K Sep 30, 2017 10-Q 2018-11-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.